Delivery Methods for Peptides and Biologics

Major drugs driving growth of the overall peptide therapeutics market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex. As these drugs lose their patent exclusivity in the near future, the market for generic peptide drugs would flourish. However, difficulty in synthesis of complex peptides has restricted growth of the generic peptide drugs market.
 
Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group. 

In response to the high incidence of discontinuation of treatment due to noncompliance, several new delivery devices have been proposed such as prefilled syringes, manual injector pens, autoinjectors, and needle-free devices. Significant improvements were also made in the field of micro/nanomechanical device-based drug delivery. These devices have shown potential in developing carriers with controlled physicochemical properties (especially size).

  • Peptide vector for biologics brain delivery

Related Conference of Delivery Methods for Peptides and Biologics

Delivery Methods for Peptides and Biologics Conference Speakers